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Middelburg, The Netherlands.The MPTP-lesioned monkey is considered as the best animal model for Parkinson’s disease (PD). It has
damage to dopaminergic cell groups and motor dysfunction similar to that seen in PD. Correlations
between these two parameters have been described but there is a lack of formal statistical analyses on
dopaminergic function as assessed by [18F]-F-DOPA PET and objectively rated motor behavior in longitu-
dinal experiments.
Eight rhesus monkeys received two MPTP infusions: ﬁrst in one carotid artery, and after eight weeks in
the other. Motor behavior and [18F]-F-DOPA uptake were measured at three stages: baseline, unilateral
and bilateral. We correlated movement with radiotracer uptake across these three stages. MPTP caused
the expected parkinsonian motor signs which were accompanied by lower radioactivity concentrations in
the striatum. There were signiﬁcant correlations between dopaminergic function and behavior.
In conclusion, striatal [18F]-F-DOPA uptake correlates inversely with the severity of motor impairment
in MPTP-lesioned non-human primates. Both behavioral scoring and [18F]-F-DOPA PET scans are useful
and sensitive methods to monitor dopaminergic degeneration within subjects.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Parkinson’s disease (PD) affects about one in a hundred people
above 65 years of age. It is best known as a movement disorder,
associated with tremor, rigidity and bradykinesia but it is also
associated with a high incidence of depression, subtle cognitive
deﬁcits and a reduced life expectancy. The most conspicuous brain
change in PD is the degeneration of dopaminergic neurons in the
substantia nigra pars compacta as found in post mortem studies.
The cause of PD is unknown and there is currently no cure.
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a syn-
thetic neurotoxin that induces parkinsonism in humans (Langston
et al., 1983) and also in monkeys (Kolata, 1983). It destroys mono-
aminergic neurons with dopaminergic neurons being especially
sensitive. As a result MPTP induces among others depletion of
dopamine in the striatum. Because of the neurochemical and
behavioral parallels, the MPTP-lesioned non-human primate is
considered as the best model for PD (Saiki et al., 2010) and it isll rights reserved.
9700 AW Groningen, The
s).
Academy, Utrecht University,used to study the pathophysiology of PD and to evaluate candidate
treatments for PD.
For the evaluation of potential neuroprotectants in PD models
and for clinical studies alike it is important to study both motor
behavior and neurochemistry. Motor behavior can be quantiﬁed
objectively for the characterisation of the severity of movement
disorders and parkinsonian symptoms in non-human primates
(Kurlan et al., 1991).
Neuroimaging of the dopaminergic system is possible with pos-
itron emission tomography (PET) or single photon emission com-
puted tomography (SPECT) in combination with a dopaminergic
tracer. SPECT can image the dopamine transporter with [dsI]-
b-CIT ([123I]-2-b-carbomethoxy-3-b-(4-iodophenyl)-tropane) and
PET can measure the dopamine synthesis capacity of the nigrostri-
atal system with [18F]-F-DOPA (6-[18F]-ﬂuoro-L-3,4-dihydroxy-
phenylalanine) or [18F]-FMT (6-[18F]-ﬂuoro-L-m-tyrosine).
There is a good correlation between post mortem and neuroim-
aging ﬁndings in humans (Snow et al., 1993). There is also a good
correlation between neuroimaging ﬁndings and clinical severity in
PD patients (Garnett et al., 1984).
For the validity of the MPTP lesioned primate as a model for PD
it is important to establish that it also displays strong correlations
between motor behavior and nigrostriatal dopaminergic function
as indexed by neuroimaging. Indeed this has been established for
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with the uptake of [123I]-b-CIT (Eberling et al., 1999) and [18F]-FMT
(Hayase et al., 1995) in that low uptake coincides with bradykine-
sia and rigidity. A correlation also exists between motor behavior
and the dopamine transporter tracer [11C]-CFT uptake in a two
group design (Saiki et al., 2010). Also for [18F]-F-DOPA, across four
groups of differentially affected MPTP lesioned monkeys, signiﬁ-
cant correlations exist between striatal [18F]-F-DOPA uptake and
motor behavior (Blesa et al., 2010). One of the few longitudinal
studies (de Yebenes et al., 1998) showed that there is an associa-
tion between motor behavior and [18F]-F-DOPA uptake but they
did not do a formal correlation analysis on their data.
What is not well established is the correlation between motor
behavior and [18F]-F-DOPA uptake within the same MPTP lesioned
monkeys, while this is typically a situation that resembles the clin-
ical situation: repeated [18F]-F-DOPA scans are used to document
disease progress within individual PD patients. We aimed to study
the correlation between motor symptoms and striatal uptake of
[18F]-F-DOPA PET in MPTP-lesioned monkeys in a quantitative
manner and hypothesized that a strong correlation would exist.
We had access to data from a longitudinal experiment in eight
monkeys in which all monkeys were scanned three times with PET.2. Materials and methods
2.1. Subjects
A total of eight right-handed young adult male rhesus monkeys
were studied under an approved protocol that met all institutional
guidelines and requirements stated in the ‘Principles of Laboratory
Care’ (NIH publication No. 85–23, revised 1985). All efforts were
made to minimise animal suffering, to reduce the number of ani-
mals used, and to utilize alternatives to in vivo techniques, if
available.
No extra monkeys were used for the current research because
they participated in a drug trial investigating a candidate neuro-
protective substance: TCH346 aka CGP3466(B) (see also (Andringa
et al., 2003)). The substance has antiapoptotic effects and a very
favourable proﬁle in animal models of neurodegenerative diseases
such as PD and multiple sclerosis (MS) (Mück-Seler and Pivac,
2000; Andringa G., 2000; Andringa et al., 2003). Unfortunately, it
failed as a neuroprotectant in both PD (Olanow et al., 2006) and
MS patients (Miller et al., 2007).
The monkeys weighed between six and twelve kilograms and
were individually housed in cages under standard conditions. Diet
consisted of lab chow supplemented with fruit while water was
available ad libitum.2.2. MPTP treatment
A two-phase bilateral MPTP lesion approach was used to gener-
ate bilateral parkinsonism. This treatment induces moderate to se-
vere parkinsonian symptoms with a signiﬁcant reduction in limb
movements and decreased striatal [18F]-F-DOPA uptake (Smith
et al., 1993).
Under total anesthesia a ﬁrst dose of 2.5 mg MPTP was admin-
istered into the carotid artery contralateral to the dominant limb
(unilateral stage) and, eight weeks later, a second dose of
1.25 mg MPTP was infused into the other carotid artery (bilateral
stage). The second dose was lower to limit incapacitation of the
animals.
Four out of the eight monkeys received TCH346 at several dose
levels for the next fourteen days after the second injection. The
other four monkeys received saline. It was assumed that while this
compound may have retarded neurodegeneration in this model, itdoes not alter the relationship between dopaminergic function and
behavior.
2.3. Assessment of motor symptoms
Motor symptoms were assessed with validated quantitative
behavioral observation. Monkeys were observed and videotaped
for 1 h on each test day: at 10 and 3 days prior to the ﬁrst MPTP
treatment (naive stage), at 6 and 7 weeks after the ﬁrst MPTP treat-
ment (unilateral stage) and at 3, 7, 14, 21, 28 and 35 days after the
second MPTP treatment (bilateral stage). A single trained investi-
gator, blind to the treatments, evaluated motor symptoms using
two different rating scales.
The ﬁrst scale was a qualitative assessment of parkinsonian
symptoms using a rating scale for non-human primates (Kurlan
et al., 1991), with minor modiﬁcations for bilaterally treated MPTP
monkeys (Smith et al., 1993). This clinically oriented rating scale
included the items: tremor, gait, akinesia/bradykinesia, balance,
rigidity/posture and food intake. The total parkinsonian symptoms
score was obtained as the sum of all items.
The second rating scale was a quantitative assessment of goal-
directed limb movements per body half (Andringa et al., 1999) and
is expressed as the percentage of time spent on goal directed limb
movements. Decreased values indicate increased parkinsonian
signs.
Given the lack of signiﬁcant differences between the values at
the several time points in each stage, these were averaged per
stage.
2.4. Scanning procedures
All monkeys were scanned at baseline (1 week prior to the ﬁrst
MPTP lesion), in the unilaterally lesioned state (7 weeks after the
ﬁrst lesion) and in the bilaterally lesioned state (ca. 5 weeks after
the second lesion).
Handling, transportation, sedation, scanning, monitoring of vital
signs, administration of drugs and radiotracer have been described
before (Kortekaas et al., 2008) but for this experiment the
anesthetic carrier gas was O2:N2O (50:50) instead of pure oxygen.
Another modiﬁcation of the previous protocol was that the periph-
eral decarboxylase inhibitor carbidopa was administered orally
(3 mg/kg) 30 min before [18F]-F-DOPA administration. The heads
were supported in a stereotactic frame and positioned centrally
in the ﬁeld of view of the scanner. An average of 98.2 MBq (range:
22–167) of [18F]-F-DOPA in 6 mL of physiological saline was in-
jected IV over one minute. Scanning was initiated immediately
and 21 frames were acquired (10  30, 3  300, 4  600, 4 
900 s, totaling 120 min). One monkey’s PET scan failed in the uni-
lateral phase due to a technical problem. Data from the unilateral
stage were not used for the correlation analyses.
2.5. PET data analysis
PET data were reconstructed to a 128  128  63 matrix with a
plane separation of 0.2425 cm and a bin size of 0.2250 cm.
Using the Clinical Applications Programming Package (Siemens,
Erlangen, Germany), regions of interest (ROIs) were placed by hand
on PET data collected from 60–120 min: elliptical ROIs were placed
on three planes over the left and right striatum, and as a reference,
on the posterior half of the brain (see Fig. 2). The reference region
included cortical grey and white matter and was of a deliberately
large size to minimize intersubject variability in placement. The
rate of speciﬁc uptake into the striatum (Kref values) relating tracer
uptake to the reference brain region, was calculated (Dhawan et al.,
2002). Mean striatal uptake was calculated as the average of left
and right striatal uptake.
Fig. 2. Position of the regions of interest (red ovals) on a [18F]-F-DOPA PET scan in
the baseline state. A transaxial slice at the level of the striatum is given with the
nose up. Small ovals contain the striatum, the large oval is a control region,
containing supracerebellar occipital cortex, that receives no measurable dopami-
nergic input. Image was made with CAPP5 (Siemens, Erlangen, Germany). (For
interpretation of color in this ﬁgure the reader is referred to the web version of this
article.)
Table 2








Baseline 10.28 ± 5.70 18.18 ± 9.70 0.0 ± 0.0
Left lesion 10.11 ± 4.70 3.94 ± 3.40 1.69 ± 1.90
Bilateral
lesion
6.26 ± 6.00 3.76 ± 2.50 9.87 ± 5.90
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For the statistical analysis, the three measurements in the eight
subjects were treated as independent because there had always
been a new lesion between any two measurements, thereby violat-
ing the assumption of dependence within subjects. Because one
PET measurement was missing, this resulted in a total of 23 obser-
vations. Because data were not normally distributed according to
the Shapiro Wilk test, we calculated Spearman’s rho, two-tailed.
A p value <0.05 was considered signiﬁcant.
3. Results
3.1. [18F]-F-DOPA uptake
Before injection of MPTP, mean [18F]-F-DOPA uptake for left and
right striatum was 0.00208 ± 0.00025 (Kref ± S.D., see Table 1). An
example of a transaxial slice through the striatum is shown in
Fig. 2.
Unilateral administration of MPTP resulted in a signiﬁcant de-
crease of left [18F]-F-DOPA striatal uptake, see Table 1 (p = 0.01;
paired t-test, two-tailed). In contrast, [18F]-F-DOPA uptake in the
right striatum was increased, but not signiﬁcantly (p = 0.16; paired
t-test, two-tailed).
After administration of MPTP into the right carotid artery,
[18F]-F-DOPA uptake in the right striatum was decreased in the
four monkeys receiving saline, although not as much as after the
ﬁrst application of MPTP. [18F]-F-DOPA uptake in the right striatum
stayed within the normal range in the TCH346 treated group. There
was no effect of the second application of MPTP on [18F]-F-DOPA
uptake in the left striatum.
3.2. Motor scores
Before injection of MPTP, all monkeys displayed normal motor
behavior (Fig. 1 and Table 2). No signs of parkinsonism wereTable 1
Striatal uptake (Kref) of [18F]-F-DOPA (mean of all monkeys ± standard deviation) for
the three experimental stages. Mean uptake is the average of left and right. Data are
presented as group mean ± standard deviation.
Stage Kref left Kref right Kref mean
Baseline 0.00211 ± 0.00039 0.00204 ± 0.00025 0.00208 ± 0.00025
Left lesion 0.00055 ± 0.00097 0.00271 ± 0.00098 N/A
Bilateral
lesion
0.00035 ± 0.00041 0.00175 ± 0.00130 0.00118 ± 0.00066
Fig. 1. Goal directed limb movements (% of the time) in the four treatment groups
over time.detected and mean parkinsonian symptoms scores were 0. Monkeys
spent more time on right than on left limb movements (Fig. 1 and
Table 2).
Administration of MPTP into the left carotid artery induced
right-sided parkinsonism in all monkeys (Fig. 1 and Table 2) as de-
scribed previously (Andringa et al., 2003), resulting in an increase
of mean parkinsonian symptoms scores. The amount of limb move-
ments on the right body half decreased, while the amount of left
sided limb movements remained in the same range as in the base-
line stage (Fig. 1 and Table 2).
In the saline treated group the second infusion of MPTP into the
right carotid artery induced parkinsonism on the left side of the
body, thus increasing the mean parkinsonian symptoms scores
(Table 2). In the four monkeys receiving TCH346, no parkinsonism
developed on the left side of the body, and mean parkinsonian
symptoms scores remained unchanged. These effects have been de-
scribed in detail elsewhere (Andringa G., 2000; Andringa et al.,
2003). The severity of parkinsonian signs on the right body side
was unaffected by the second MPTP treatment. Time spent on left
limb movements was reduced in the saline group, but not in the
TCH346 treated group. Also, no effect was noticed of the second
infusion of MPTP on right limb movements.3.3. Correlation between motor symptoms and [18F]-F-DOPA uptake
Mean parkinsonian symptoms scores were highly signiﬁcantly
and negatively correlated with mean striatal uptake of
Fig. 3. Highly signiﬁcant negative correlation between mean striatal [18F]-F-DOPA
uptake (Kref) and total parkinsonian symptoms scores. (Spearman’s q = 0.735,
p = 0.001). Both observations from eight monkeys were treated as independent.
Table 3
Correlations (q-Spearman’s rho) between striatal [18F]-F-DOPA uptake (Kref) and
behavioral data. Correlations were calculated over Baseline and Bilateral lesion stages.
Correlation q p
Mean striatal [18F]-F-DOPA
Uptake vs. total parkinsonian symptoms scores
–0.735 0.001
Left striatal [18F]-F-DOPA
Uptake vs. right limb movements
0.576 0.019
Right striatal [18F]-F-DOPA
Uptake vs. left limb movements
0.333 0.208
Fig. 4. Signiﬁcant positive correlation between left striatal [18F]-F-DOPA uptake
(Kref) and right limb movements (% of the time). (Spearman’s q = 0.576, p = 0.019).
Both observations from eight monkeys were treated as independent.
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Table 3).
A signiﬁcant positive relationship was found between left
striatal [18F]-F-DOPA uptake and right limb movements (Fig. 4 and
Table 3).
The relationship between right striatal [18F]-F-DOPA uptake and
left limb movements was not signiﬁcant (Table 3).
Linear ﬁts were not statistically signiﬁcantly different from
non-linear ﬁts.4. Discussion
4.1. Validity of [18F]-F-DOPA scanning in MPTP monkeys
Not many studies have systematically correlated motor symp-
toms with striatal [18F]-F-DOPA uptake in the MPTP lesioned mon-
key in a longitudinal design. This is relevant because the MPTPmonkey is a highly valid PD model and [18F]-F-DOPA is used in
the clinic to monitor the degradation of nigrostriatal system func-
tion within individual PD patients.
We found signiﬁcant correlations between: (i) total parkinso-
nian symptoms scores and mean striatal [18F]-F-DOPA uptake and
between (ii) lateralized limb movements and contralateral [18F]-F-
DOPA uptake in MPTP lesioned monkeys (for left striatum and
right limbs).
This ﬁnding of signiﬁcant correlations between motor scores
and dopamine function in MPTP-lesioned monkeys is in agreement
with previous studies using [123I]-b-CIT SPECT (Eberling et al.,
1999) and [18F]-FMT PET (Eberling et al., 1998; Eberling et al.,
2000). Our data are also in agreement with a previous study (de
Yebenes et al., 1998) which showed that in MPTP lesioned mon-
keys there was a correspondence between motor behavior and
[18F]-F-DOPA uptake. We extended this study to a three-scan de-
sign and by adding a statistical analysis of the correlation between
motility and [18F]-F-DOPA uptake. Similarly, we extended the pre-
vious ﬁnding that signiﬁcant correlations exist between striatal
[18F]-F-DOPA uptake and motor behavior across monkeys (Blesa
et al., 2010) to the within subjects situation where the same mon-
keys are scanned repeatedly.
We conﬁrm that behavioral observation by means of video-
taping and a qualitative rating scale is a sensitive and reliable
tool for assessment of nigrostriatal function in monkeys (Saiki
et al., 2010) and also that it correlates with neurochemical prop-
erties of the dopaminergic system as measured with PET (Saiki
et al., 2010).
A recent study in PD patients (de la Fuente-Fernández, 2012) re-
ported that the accuracy of a clinical diagnosis of PD is very high
and identical to the accuracy of a SPECT based diagnosis. This is
in agreement with the ﬁndings presented here because our behav-
ioral and neurochemical endpoints were also both very accurate at
identifying animals with dopaminergic lesions.4.2. Methodological considerations
The two different treatment regimes in terms of TCH346 re-
sulted in a wide range of severity of the MPTP lesions and therefore
also in striatal [18F]-F-DOPA uptake and parkinsonian motor signs.
Such a wide range in motor dysfunction and [18F]-F-DOPA uptake
is advantageous for a regression analysis on these parameters.
We assumed that TCH346 does not alter the relationship be-
tween striatal dopaminergic uptake and motor behavior, as both
are altered in a consistent manner. This is supported by the ﬁnding
that the correlations between motor scores and striatal uptake
were similar in all treatment groups. However, this has not been
tested with experimental data and a possible effect of TCH346 on
the relation between the two parameters cannot be ruled out.
In the non-lesioned phase we found a mean Kref of 0.002. This is
in the same range as the results of others (Doudet et al., 1999). The
fact that some of our Kref values were negative is due to the fact
that Kref is a random variable with random noise so that the ‘spot
estimate’ can be negative if the true Kref is zero or close to zero.
The correlation between right sided striatal [18F]-F-DOPA up-
take and left limb movements was not statistically signiﬁcant. The
lack of signiﬁcance is explained by the fact that all monkeys were
right-handed so that the values for left limb movements were half
as large as the contralateral movement values. Also, the left MPTP
dose was half as large as the right dose.
In our statistical analyses, we considered all data points as inde-
pendent observations, although these are not completely indepen-
dent from each other because they are obtained from the same
animals. However, the intra-individual dependence largely disap-
pears with each administration of MPTP.
R. Kortekaas et al. / Neurochemistry International 62 (2013) 349–353 3534.3. Summary
In conclusion, striatal [18F]-F-DOPA uptake correlates with
behavioral measures in MPTP-treated monkeys, not only in parallel
but also in longitudinal experimental designs. Both [18F]-F-DOPA
PET and quantitative objective behavioral assessment are robust
and reliable methods for assessing the functional integrity of the
nigrostriatal dopaminergic system.
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